Physician profile
Michael Habib
NPI 1376678276
$2,826.33
in general payments reported to CMS, 2019-2025
24 companies · $471 in 2025
The $471 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $254 · 2021: $514 · 2022: $497 · 2023: $289 · 2024: $413 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $505.02 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $482.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $301.05 | 2021-2025 | Verquvo, Steglatro |
| Novo Nordisk INC | $216.39 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $197.09 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.11 | 2019-2025 | Jardiance |
| Pfizer INC. | $159.79 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.36 | 2022-2025 | |
| Medtronic Vascular, INC. | $109.88 | 2019 | |
| Cardiva Medical, INC. | $97.64 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $92.47 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $42.53 | 2020-2022 | |
| Inari Medical, INC. | $42.50 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $39.66 | 2019-2025 | Eliquis |
| Lexicon Pharmaceuticals, INC. | $38.58 | 2023-2024 | Inpefa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $33.03 | 2024-2025 | Opsumit, Uptravi |
| Stryker Corporation | $28.96 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cardiovascular Systems INC. | $17.85 | 2021 | |
| Glaxosmithkline, LLC. | $17.02 | 2025 | Shingrix, Arexvy |
| Allergan, INC. | $17.00 | 2019 | |
| Biotronik INC. | $16.89 | 2024 | Pulsar-18 T3, Passeo-18 |
| Viatris Specialty LLC | $16.56 | 2025 | Yupelri |
| Arbor Pharmaceuticals, INC. | $14.00 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.19 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Habib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.